Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

Summary

A phase II, multi-center, open-label, single-arm, non-randomized study to evaluate the efficacy, safety and tolerability of IMP4297 capsules in subjects with germline and/or somatic BRCA1/2 mutated advanced ovarian cancer in china

Timeline

Start

2019-10-28

Primary completion

2023-06-30

Completion

2024-12-17

Drugs

Indications